Abstracts tagged "Inflammation"

Abstract Number: 0693 • ACR Convergence 2020
Effect of Physical Activity on Cartilage Degradation and Inflammation in Individuals with Lumbar Spinal Stenosis
Gustavo Almeida¹, Samannaaz Khoja², Lauren Terhorst³, Gwendolyn Sowa⁴, Sara Piva² and Michael Schneider², ¹Department of Physical Therapy, UT HEALTH SAN ANTONIO, San Antonio, TX, ²Department of Physical Therapy, University of Pittsburgh, Pittsburgh, PA, ³Department of Occupational Therapy, University of Pittsburgh, Pittsburgh, PA, ⁴Department of Physical Medicine and Rehabilitation, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Guidelines recommend 150 minutes a week in moderate-intensity physical activity (MPA) to improve health in individuals with chronic disease such as those with lumbar…
Abstract Number: 0945 • ACR Convergence 2020
Neutrophils Mediate Kidney Inflammation Following Acute Skin Exposure to UV Light
Sladjana Skopelja-Gardner¹, Joyce Tai², Xizhang Sun², Lena Tanaka², James Kuchenbecker², Tomas Mustelin¹ and Keith Elkon², ¹University of Washington, Seattle, WA, ²University of Washington, Seattle
Background/Purpose: Sensitivity to ultraviolet (UV) light affects up to 80% of SLE patients and can exacerbate systemic disease flares, including lupus nephritis (LN). Our findings…
Abstract Number: 1233 • ACR Convergence 2020
Use of Multi-Biomarker Disease Activity Scores to Compare Biosimilar Adalimumab-afzb (PF-06410293) with EU-Sourced Reference Adalimumab in a Phase 3, Randomized, Double-Blind Trial in Patients with Active RA
Jonathan Kay¹, Amy Bock², Noriko Iikuni³, Wuyan Zhang⁴ and Daniel Alvarez⁵, ¹University of Massachusetts Medical School, Worcester, MA, ²Pfizer, Cambridge, MA, ³Pfizer, New York, NY, ⁴Pfizer, New York, ⁵Pfizer, Collegeville, PA
Background/Purpose: Traditional efficacy endpoints of disease activity (DA) in studies of anti-rheumatic drugs can be confounded by subjective (patient-/physician-reported) assessments, comorbidities, and pre-existing joint damage.…
Abstract Number: 1569 • ACR Convergence 2020
Immune Related Adverse Events Related to Check Point Inhibitors Among Outpatients in an Academic Center
Bushra Akram¹, Aleena Itani¹, Mohammad Razaq², Samera Vaseer¹, Sara Vesely¹ and Pawan Acharya¹, ¹University of Oklahoma Health Sciences Center, Oklahoma City, ²University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: Immune check point inhibitors (ICIs) allow the body to recognize tumor cells as non-self, resulting in immune-cell mediated tumor cell destruction. These therapies have the…
Abstract Number: PP03 • ACR Convergence 2020
Connecting with Rheumatology Professionals and Thought Leaders Inspired the Creation of a New Program Focused on Relapsing Polychondritis (“RP”), a Rare Rheumatic Disease: Participating at ACR Annual Meetings Has Provided Exceptional Opportunities to Learn and Build Relationships
Nancy Linn¹, Catherine Bammert², David Bammert³ and Michael Linn⁴, ¹Relapsing Polychondritis Foundation, Palos Verdes Estates, CA, ²MD Anderson, Houston, TX, ³Relapsing Polychondritis Foundation, Houston, TX, ⁴Relapsing Polychondritis Foundation, New York, NY
Background/Purpose: In 2011, I was diagnosed with relapsing polychondritis ("RP"), a debilitating and sometimes fatal rheumatic disease that is characterized by inflammation of cartilage and…
Abstract Number: 0366 • ACR Convergence 2020
Symptoms of Peripheral Arthritis Are Significantly Improved in Patients with Ankylosing Spondylitis Treated with Secukinumab
Philip Mease¹, Atul Deodhar², Renato Calheiros³, Xiangyi Meng⁴, Todd Fox⁵ and Xenofon Baraliakos⁶, ¹Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ²Oregon Health & Science University, Portland, OR, ³Novartis Pharmaceuticals Corporation, Hoboken, NJ, ⁴Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁵Novartis Pharma AG, Aesch, Switzerland, ⁶Rheumazentrum Ruhrgebiet-Ruhr-University Bochum, Herne, Germany
Background/Purpose: Ankylosing spondylitis (AS) is a chronic inflammatory disease of the axial skeleton associated with pain, stiffness, and disability.1 Up to 66% of patients (pts)…
Abstract Number: 0700 • ACR Convergence 2020
Lipoxin A4 Induces Lipid Class Switching and Inflammation Resolution at the Genomic Level in Human Osteoarthritis
Mandar Dave¹, Abul Islam², Akshat Parekh³, Jay Patel⁴, Arushi Chawla⁵ and Ashok Amin⁶, ¹Department of Rheumatology and Pathology, New York University Hospital for Joint Diseases, New York, ²Department of Genetic Engineering and Biotechnology, University of Dhaka, Dhaka, Bangladesh, ³Rutgers Robert Wood Johnson Medical School, Piscataway, NJ, ⁴Northeast Ohio Medical University, Rootstown, OH, ⁵Gujarat Forensic Science University, Gujarat, India, ⁶Department of Rheumatology and Pathology, New York University Hospital for Joint Diseases, New York, NY
Background/Purpose: Human OA-affected cartilage does not show the cardinal signs of inflammation (redness and swelling with heat and pain—rubor et tumor cum calore et dolor) because…
Abstract Number: 0946 • ACR Convergence 2020
ENPP1 Regulates UV Light Triggered Type I Interferon Response in the Skin
Sladjana Skopelja-Gardner¹, Joyce Tai², Xizhang Sun² and Keith Elkon², ¹University of Washington, Seattle, WA, ²University of Washington, Seattle
Background/Purpose: Systemic lupus erythematosus (SLE) patients have a prominent type I interferon (IFN-I) signature in both the lesional and non-lesional skin. We recently showed that…
Abstract Number: 1237 • ACR Convergence 2020
Pain and Other Patient-Reported Outcomes in Patients with Rheumatoid Arthritis Who Did or Did Not Achieve Treatment Response Based on Improvement in Swollen Joints in Tocilizumab Clinical Trials
Anthony Sebba¹, Jian Han² and Shalini V. Mohan², ¹Arthritis Associates, Palm Harbor, Tampa, FL, ²Genentech, South San Francisco, CA
Background/Purpose: Recent data suggest that rheumatoid arthritis (RA) pain may be noninflammatory and inflammatory, and improvement in pain scores and other patient-reported outcomes (PROs) may…
Abstract Number: 1577 • ACR Convergence 2020
Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis Impact on Function and Patient-Reported Quality of Life Measures Varies Depending on Pattern of Arthritis
Jeffrey Sarazin¹, Ann Impens², Nada Abdulaziz¹, Stacey Anderson³, Leslie Fecher¹, Christopher Lao¹ and Elena Schiopu¹, ¹Michigan Medicine, Ann Arbor, MI, ²Midwestern University, Ann Arbor, IL, ³University of Michigan, Ann Arbor, MI
Background/Purpose: Immune checkpoint inhibitors (ICIs) have emerged as a paradigm shift in the treatment of malignancies, but can have significant side effects, termed immune related…
Abstract Number: PP04 • ACR Convergence 2020
My Multidisciplinary Healthcare Team and Patient Advocacy Groups Saved My Life
Tedi LaMere¹, Michael Linn² and David Bammert³, ¹Relapsing Polychondritis Foundation, Kalispell, MT, ²Relapsing Polychondritis Foundation, New York, NY, ³Relapsing Polychondritis Foundation, Houston, TX
Background/Purpose: I enjoyed being physically active my entire life – climbing mountains, hunting, and hiking. This drastically changed around 2012, when I noticed that I was…
Abstract Number: 0381 • ACR Convergence 2020
Efficacy of Tofacitinib on Dactylitis in Individual Digits in Patients with Active Psoriatic Arthritis
Ana-Maria Orbai¹, Philip Mease², Philip Helliwell³, Oliver FitzGerald⁴, Mohamed Bedaiwi⁵, Dona Fleishaker⁶, Rajiv Mundayat⁶ and Pamela Young⁷, ¹Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ³Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁴Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland, ⁵Division of Rheumatology, College of Medicine, King Saud University Medical City, King Saud University, Riyadh, Saudi Arabia, ⁶Pfizer Inc, Groton, CT, ⁷Pfizer Inc, Collegeville, PA
Background/Purpose: Dactylitis, a hallmark of psoriatic arthritis (PsA), is a uniformly diffuse and sometimes painful swelling of the fingers and/or toes.1 Up to 50% of…
Abstract Number: 0705 • ACR Convergence 2020
lncRNA H19 and Micro RNA 675-3p Are Altered by Visfatin During Osteogenesis
Dennis Küppers¹, Lali Tsiklauri², Marie-Lisa Hülser¹, Klaus Frommer², Stefan Rehart³, Caroline Ospelt⁴, Ulf Müller-Ladner⁵ and Elena Neumann⁶, ¹Justus-Liebig-University Giessen, Campus Kerckhoff, Dept. of Rheumatology and Clinical Immunology, Giessen, Germany, ²Justus-Liebig-University Giessen, Campus Kerckhoff, Dept. of Rheumatology and Clinical Immunology, Bad Nauheim, Germany, ³Department of Orthopaedics and Trauma Surgery, Agaplesion Markus Hospital, Frankfurt, Frankfurt, Germany, ⁴University Hospital Zürich; University Hospital of Zurich; Center of Experimental Rheumatology, Department of Rheumatology, Zurich, Switzerland, ⁵Department of Rheumatology, Immunology, Osteology and Physical Medicine, Justus Liebig University Gießen, Campus Kerckhoff, Bad Nauheim, Germany, Bad Nauheim, Germany, ⁶Department of Rheumatology and Clinical Immunology, Campus Kerckhoff, Justus Liebig University Giessen, Bad Nauheim, Germany
Background/Purpose: Long non-coding (lnc-)RNAs are transcribed from DNA similar to mRNA. lncRNA are able to interact directly with DNA, RNA and proteins. Some lncRNAs contain…
Abstract Number: 0949 • ACR Convergence 2020
SLAMF7 Engagement Drives Monocyte Super-Activation in Acute and Chronic Inflammation
Daimon Simmons¹, Hung Nguyen², Emma Gomez-Rivas³, YunJu Jeong⁴, William Apruzzese⁵, Edy Kim⁶ and Michael Brenner⁷, ¹Department of Pathology, Brigham and Women's Hospital, Boston, MA, ²Division of Rheumatology, Brigham and Women's Hospital,, Boston, MA, ³Division of Rheumatology, Brigham and Women's Hospital, Boston, MA, ⁴Division of Pulmonary and Critical Care, Brigham and Women's Hospital, Boston, MA, ⁵., Boston, ⁶Brigham and Women’s Hospital, Division of Pulmonary and Critical Care Medicine, Boston, MA, ⁷Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Monocytes orchestrate immune responses that protect against microbes but can also drive pathological inflammation and autoimmune disease. Monocytes are thought to be activated primarily…
Abstract Number: 1240 • ACR Convergence 2020
An Increase in Red Cell Mean Corpuscular Volume by Methotrexate Is Potentiated by Hydroxychloroquine and Predicts Clinical Response in Rheumatoid Arthritis
Muhammad Shipa¹, Su-Ann Yeoh¹, Dev Mukerjee² and Michael Ehrenstein¹, ¹University College London, LONDON, United Kingdom, ²North Middlesex University hospital NHS Trust, London, United Kingdom
Background/Purpose: Methotrexate (MTX) can result in an increase in mean corpuscular volume (MCV) of red blood cells. The range of MCV change varies between patients…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].